Kristoffer Haugarvoll
Overview
Explore the profile of Kristoffer Haugarvoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boyle L, Giriteka L, Marty B, Sandgathe L, Haugarvoll K, Steihaug O, et al.
Sensors (Basel)
. 2025 Feb;
25(3).
PMID: 39943307
Background: With a progressively aging global population, the prevalence of Parkinson's Disease and dementia will increase, thus multiplying the healthcare burden worldwide. Sensing technology can complement the current measures used...
2.
Boyle L, Marty B, Haugarvoll K, Steihaug O, Patrascu M, Husebo B
J Biomed Inform
. 2025 Jan;
162:104781.
PMID: 39864718
Background: Increased prevalence of neurodegenerative diseases complicates care needs for older adults. Sensing technologies, such as smartwatches, are one available solution which can help address the challenges of aging. Knowledge...
3.
Stige K, Kverneng S, Sharma S, Skeie G, Sheard E, Sognen M, et al.
Prog Neurobiol
. 2024 Apr;
236:102603.
PMID: 38604582
The STRAT-PARK initiative aims to provide a platform for stratifying Parkinson's disease (PD) into biological subtypes, using a bottom-up, multidisciplinary biomarker-based and data-driven approach. PD is a heterogeneous entity, exhibiting...
4.
Titlestad I, Haugarvoll K, Solvang S, Norekval T, Skogseth R, Andreassen O, et al.
Age Ageing
. 2024 Feb;
53(2).
PMID: 38342753
Background: In-hospital delirium is associated with adverse outcomes and is underdiagnosed, limiting research and clinical follow-up. Objective: To compare the incidence of in-hospital delirium determined by chart-based review of electronic...
5.
Berven H, Kverneng S, Sheard E, Sognen M, Af Geijerstam S, Haugarvoll K, et al.
Nat Commun
. 2023 Nov;
14(1):7793.
PMID: 38016950
Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson's disease (PD) and other neurodegenerative disorders. However, the optimal dose of NR remains unknown, and doses...
6.
Gaare J, Dolle C, Brakedal B, Brugger K, Haugarvoll K, Nido G, et al.
iScience
. 2023 Mar;
26(3):106278.
PMID: 36936793
Replenishing nicotinamide adenine dinucleotide (NAD) via supplementation of nicotinamide riboside (NR) has been shown to confer neuroprotective effects in models of aging and neurodegenerative diseases, including Parkinson's disease (PD). Although...
7.
Brakedal B, Toker L, Haugarvoll K, Tzoulis C
NPJ Parkinsons Dis
. 2022 Mar;
8(1):19.
PMID: 35236852
Epidemiological studies of Parkinson's disease (PD) show variable and partially conflicting findings with regard to incidence, prevalence, and mortality. These differences are commonly attributed to technical and methodological factors, including...
8.
Brakedal B, Dolle C, Riemer F, Ma Y, Nido G, Skeie G, et al.
Cell Metab
. 2022 Mar;
34(3):396-407.e6.
PMID: 35235774
We conducted a double-blinded phase I clinical trial to establish whether nicotinamide adenine dinucleotide (NAD) replenishment therapy, via oral intake of nicotinamide riboside (NR), is safe, augments cerebral NAD levels,...
9.
Brakedal B, Tzoulis C, Tysnes O, Haugarvoll K
PLoS One
. 2021 Sep;
16(9):e0256602.
PMID: 34492069
Objective: Whether use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of incident Parkinson's disease (PD) remains unresolved. Here, we employed the Norwegian Prescription Database to examine whether NSAID use...
10.
Toker L, Tran G, Sundaresan J, Tysnes O, Alves G, Haugarvoll K, et al.
Mol Neurodegener
. 2021 May;
16(1):31.
PMID: 33947435
Background: Parkinson's disease (PD) is a complex, age-related neurodegenerative disorder of largely unknown etiology. PD is strongly associated with mitochondrial respiratory dysfunction, which can lead to epigenetic dysregulation and specifically...